title: A new cell line from human undifferentiated carcinoma of the ovary: establishment and characterization.
abstract: A cell line designated CUMO-2 has been established from an undifferentiated ovarian carcinoma. The s.c. injection of cells into nude mice gave rise to fast-growing tumors, while the i.p. route induced a peritoneal carcinomatosis with ascites. Histopathologically, the transplanted s.c. tumors closely resembled the original tumor, but tumors developed in the peritoneal cavity were highly anaplastic. The epithelial nature of the cells was confirmed by ultrastructural analysis. Sequential cytogenetic analyses on early and late passages revealed highly aneuploid tumor cells with consistent structural aberrations of chromosomes 1, 3, 8 and 11. CUMO-2 cells were found to produce CA 125 in vitro and in vivo. Cytosol estrogen receptor (ER) was found but progesterone receptor (PR) was not measured. HLA typing indicated the presence of DR8 and DQw4. A gonadotropin-releasing hormone (Gn-RH) analog inhibited cell growth and Gn-RH receptor mRNA was detected by reverse transcription/polymerase chain reaction in this cell line. Administration of transforming growth factor beta 1 inhibited both cell growth and c-myc mRNA expression. This cell line demonstrated a conformational band shift in exon 7 of the p53 gene. It was a frameshift mutation.
authors.affiliation: Department of Obstetrics and Gynecology, Kangnam St. Mary's Hospital, Catholic University Medical College, Seoul, Korea.
authors.forename: J W
authors.initials: JW
authors.lastname: Kim
authors.forename: C G
authors.initials: CG
authors.lastname: Lee
authors.forename: M S
authors.initials: MS
authors.lastname: Lyu
authors.forename: H K
authors.initials: HK
authors.lastname: Kim
authors.forename: J G
authors.initials: JG
authors.lastname: Rha
authors.forename: D H
authors.initials: DH
authors.lastname: Kim
authors.forename: S J
authors.initials: SJ
authors.lastname: Kim
authors.forename: S E
authors.initials: SE
authors.lastname: Namkoong
mesh_terms: D000818:Animals; D018394:CA-125 Antigen / Q000096:biosynthesis; D002277:Carcinoma / Q000737:chemistry / Q000235:genetics / Q000473:pathology*; D002454:Cell Differentiation; D002455:Cell Division; D002460:Cell Line; D002871:Chromosome Banding; D005260:Female; D015870:Gene Expression; D016259:Genes, myc; D006131:Growth Inhibitors / Q000494:pharmacology; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000737:chemistry / Q000235:genetics / Q000473:pathology*; D018807:Polymorphism, Single-Stranded Conformational; D012333:RNA, Messenger / Q000235:genetics; D012334:RNA, Neoplasm / Q000235:genetics; D011960:Receptors, Estrogen / Q000032:analysis; D011966:Receptors, LHRH / Q000235:genetics; D016212:Transforming Growth Factor beta / Q000494:pharmacology
chemical_list: D018394:CA-125 Antigen; D006131:Growth Inhibitors; D006680:HLA Antigens; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011960:Receptors, Estrogen; D011966:Receptors, LHRH; D016212:Transforming Growth Factor beta